[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-45066e9f-55f0-4390-9b37-870ed6b58eb7--":3,"related-articles-undefined-undefined-30e76681-639e-4fbd-b386-b506ba4fee17-true":20},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"organisationTitle":9,"thirdParty":10,"body":11,"city":12,"website":13,"orgId":14,"branches":15,"description":19},"45066e9f-55f0-4390-9b37-870ed6b58eb7","PRESSRELEASE","Matisse Pharmaceuticals strengthens Scientific Board with Profs. J. Marshall & M. Singer","2023-05-23T13:04:13.087+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Ffile\u002Flogos\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002F6980a729-3571-4cff-a3ed-51c20c6e1da3.jpg","Matisse Pharmaceuticals B.V.",false,"\u003Cp>\u003Cem>Matisse Pharmaceuticals strengthens Scientific Advisory Board with Prof. John Marshall and Prof. Mervyn Singer\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, is glad to announce that it has been able to strengthen its scientific advisory board with two very experienced and worldwide renowned experts in the field of sepsis and intensive care medicine.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>“Matisse is entering a crucial phase in the development of the company. We are currently close to finalizing our phase 1\u002F2a study for our lead compound for the treatment of sepsis and septic shock in patients in an ICU setting. With the data generated, we are able to fine-tune our further development steps. We are happy that Mervyn and John have agreed to support us in challenging us on clinical and scientific steps forward” according to Kees Groen, CEO of Matisse Pharmaceuticals.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Prof. John Marshall \u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>John Marshall is a Professor of Surgery and Critical Care Medicine at the University of Toronto, and a Senior Scientist in the Li Ka Shing Knowledge Institute of Unity Health Toronto.  He received his medical degree from the University of Toronto, followed by post-graduate training at Dalhousie University in Halifax and McGill University in Montreal.  He is the rounding and current Chair of the International Forum for Acute Care Trialists (InFACT), past-Chair of the International Sepsis Forum (ISF) and the Canadian Critical Care Trials Group (CCCTG), former Secretary-General of the World Federation of Societies of Intensive and Critical Care (WFSICC), and past-President of the Surgical Infection Society (SIS).  He is an Associate Editor of the journal, Critical Care, and a Senior Editor of Critical Care Medicine.  He has published more than 500 peer-reviewed manuscripts, and has been cited more than 150,000 times (Google Scholar).  He has a long-standing interest in host-microbial interactions, and in sepsis clinical trials, as well as a laboratory interest in the cellular mechanisms that regulate neutrophil survival.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Prof. Mervyn Singer\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Mervyn Singer is Professor of Intensive Care Medicine at University College London, UK.\u003C\u002Fp>\n\u003Cp>His research career began with the development of a haemodynamic monitor (oesophageal Doppler), now in use in >30 countries worldwide. He subsequently developed his interests in sepsis, infection, ischaemia-reperfusion injury and multiple organ failure with complementary studies in basic, translational and clinical research. He has a particular passion for the role of mitochondrial dysfunction in sepsis, publishing a seminal clinical paper in the Lancet in 2002. With clinicians and engineers at UCL\u002FUCLH and Mercedes HPP, he led the production of a non-invasive respiratory support (CPAP) device for use during the COVID-19 pandemic; He currently has two novel drugs (for sepsis and ischaemia-reperfusion injury) and two novel monitors in development. He was the first UK intensivist to be awarded NIHR Senior Investigator status. He has authored and edited multiple textbooks including the Oxford Handbook of Critical Care and the Oxford Textbook of Critical Care. He co-chaired the ‘Sepsis-3’ international consensus committee that developed the latest sepsis definitions. The subsequent paper (Singer et al, JAMA 2016) has had >3.7 million views and been cited in >11500 publications. He has chaired the International Sepsis Forum, and sat on the Surviving Sepsis Campaign committee, various UK Department of Health\u002FNHS advisory\u002Fresearch funding boards, and numerous industry advisory boards for novel drugs, monitors and diagnostics.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Matisse Scientific Advisory Board\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Prof. Chris Reutelingsperger chairs the Matisse Scientific Advisory board. Prof. Tom van der Poll and Associate Professor Robert Frithiof will also continue as a member of the Scientific Advisory Board now complemented by Prof. John Marshall and Prof. Mervyn Singer.  \u003C\u002Fp>\n\u003Cp>\u003Cstrong>About M6229\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>Matisse’s platform technology is based on the discovery that in many patients suffering from sepsis, proteins called histones are released by the innate immune system and dying cells into the blood stream, where they are toxic to other cells. Due to a self-enforcing cascade, people may die from organ failure within one or two days. Preclinical results have shown that by neutralizing the toxic histones with Matisse’s product M6229, the negative cascade is terminated by neutralization of cationic histones by anionic M6229. Matisse claims to have identified an elegant solution for treating sepsis by using a non-anticoagulant fraction of heparin called M6229 to neutralize toxic circulatory histones. Currently, there is no effective treatment against sepsis. From the 50 million patients globally suffering from sepsis every year, some 20% die. According to a recent J. Crit .Care Med. study, sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone.\u003C\u002Fp>\n\u003Cp>​\u003Cimg alt=\"John Marschall\" width=\"500\" height=\"613\" src=\"https:\u002F\u002Fstorage.googleapis.com\u002Faps-attachments\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002Fae0d05fa-d472-485f-87ad-5d5a8e824f97\u002FJohnMarschall.jpg\" \u002F>\u003C\u002Fp>\n\u003Cp>\u003Cem>On the photo: John Marschall\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>\u003Cimg alt=\"Mervyn Singer\" width=\"500\" height=\"250\" src=\"https:\u002F\u002Fstorage.googleapis.com\u002Faps-attachments\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002Fae0d05fa-d472-485f-87ad-5d5a8e824f97\u002FMervynSinger.jpg\" \u002F>\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cem>On the photo: Mervyn Singer\u003C\u002Fem>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>About Matisse Pharmaceuticals\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Ca target=\"_blank\" href=\"https:\u002F\u002Fwww.matissepharmaceuticals.com\u002F\">Matisse Pharmaceuticals BV\u003C\u002Fa> was founded in 2014 in Geleen, the Netherlands. Matisse targets life-threatening inflammation by neutralizing cytotoxic components of the inflammatory system. Its main development program is the development of a medicine to fight sepsis and septic shock, which is currently in clinical phase.\u003C\u002Fp>","Geleen","https:\u002F\u002Fwww.matissepharmaceuticals.com\u002F","30e76681-639e-4fbd-b386-b506ba4fee17",[16],{"id":17,"title":18},"26100","Economie en geld","Matisse Pharmaceuticals strengthens Scientific Advisory Board with Prof. John Marshall and Prof. Mervyn Singer Matisse Pharmaceuticals B.V., a clinical stage co",[21,32,41,51,58,65,74,77,85],{"id":22,"title":23,"pubDate":24,"logoUrl":8,"thirdParty":10,"imageUrls":25,"orgId":14,"branches":27,"description":31},"bd9fde26-b811-4628-8b39-f5666e6ef8a4","Matisse Pharmaceuticals en EpiDisease ontvangen EU-financiering voor eHISTOCURE-project","2025-06-26T10:00:00.031+02:00",[26],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002Fbd9fde26-b811-4628-8b39-f5666e6ef8a4\u002F20250626ENMatissereceivesEurostarsgrantLI.pdf",[28],{"id":29,"title":30},"29100","Zorg","Geleen, 26 juni, 2025. Matisse Pharmaceuticals B.V., een bedrijf dat momenteel een geneesmiddel in de klinische ontwikkelingsfase heeft voor de behandeling van ",{"id":33,"title":34,"pubDate":35,"logoUrl":8,"thirdParty":10,"imageUrls":36,"orgId":14,"branches":38,"description":40},"7440985c-cb18-4aa7-a0fb-0e4b98c52849","Matisse krijgt goedkeuring van BfArM voor studie naar een langdurig infuus met M6229","2024-10-24T10:00:00.044+02:00",[37],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002F7440985c-cb18-4aa7-a0fb-0e4b98c52849\u002F20241024FinalPressReleaseMatisseHVstudyENL.pdf",[39],{"id":29,"title":30},"Geleen, 24 oktober, 2024 Matisse Pharmaceuticals B.V., een bedrijf dat een geneesmiddel ontwikkelt voor de behandeling van sepsis, heeft vandaag aangekondigd da",{"id":42,"title":43,"pubDate":44,"logoUrl":8,"thirdParty":10,"imageUrls":45,"orgId":14,"branches":48,"description":50},"8d7ed437-110f-4571-919b-791466574383","Matisse Pharmaceuticals benoemt prof. Carolyn Calfee tot lid van de Wetenschappelijke Raad","2024-10-22T10:00:00.041+02:00",[46,47],"https:\u002F\u002Flh3.googleusercontent.com\u002Fe8cWlW3xFNCB3OT6TI_oegCqJYaz-knhgdDnFcaS3J8_G4VKMhOxz4OAYVw7BeL6p3JHy6GTMTWfgPllhOscUSKO2s48N4gykxo","https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002F8d7ed437-110f-4571-919b-791466574383\u002F20241022FinalPressReleaseMatisseappointsCarolynCalfeetoScientificBoardENL.pdf",[49],{"id":29,"title":30},"Geleen, 22 oktober, 2024 Matisse Pharmaceuticals B.V., een bedrijf dat een geneesmiddel ontwikkelt voor de behandeling van sepsis, kondigt de benoeming aan van ",{"id":52,"title":53,"pubDate":54,"logoUrl":8,"thirdParty":10,"orgId":14,"branches":55,"description":57},"57d8e5c0-87f5-43cd-8d96-f696a0e6037a","Matisse Pharmaceuticals behaalt primaire doelstellingen in studie bij sepsispatiënten","2024-01-30T11:00:00.163+01:00",[56],{"id":29,"title":30},"Matisse Pharmaceuticals B.V., een bedrijf dat een geneesmiddel ontwikkelt voor de behandeling van sepsis, heeft vandaag de eerste resultaten bekendgemaakt van d",{"id":59,"title":60,"pubDate":61,"logoUrl":8,"thirdParty":10,"orgId":14,"branches":62,"description":64},"b556e2bd-956d-4820-9151-eee34f8aa152","Matisse Pharmaceuticals closes EUR 3.6 million financing round","2024-01-04T11:30:00.029+01:00",[63],{"id":29,"title":30},"Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, is pleased to announce that has finalized a s",{"id":66,"title":67,"pubDate":68,"logoUrl":8,"thirdParty":10,"imageUrls":69,"orgId":14,"branches":71,"description":73},"cd533176-c13a-4247-b065-8093bec622dd","Matisse Pharmaceuticals appoints Marcel Jacobs as CEO","2024-01-02T12:49:51.604+01:00",[70],"https:\u002F\u002Flh3.googleusercontent.com\u002FeTjYX2Y1ZAevJLJhDTh2vD0RbvwHuJfsPNhWP08ztmrT0NEm_MzlO_S_ltH618SimQr8q5tEbea4lI56zLeqplRt0JrPI4vJ",[72],{"id":29,"title":30},"Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, is pleased to announce that it has appointed ",{"id":4,"title":6,"pubDate":7,"logoUrl":8,"thirdParty":10,"orgId":14,"branches":75,"description":19},[76],{"id":17,"title":18},{"id":78,"title":6,"pubDate":79,"logoUrl":8,"thirdParty":10,"imageUrls":80,"orgId":14,"branches":83,"description":19},"ae0d05fa-d472-485f-87ad-5d5a8e824f97","2023-05-23T12:30:00.030+02:00",[81,82],"https:\u002F\u002Flh3.googleusercontent.com\u002FvE7grMlX9atlG7-hcLFa3hhRjRaW70gCvOv0X_Oi2fSTPpd1IuUVVC2Y5_0rKYV0Sp5Y4_m-ADSTp7iISI9j7P28evjoZRDauw","https:\u002F\u002Flh3.googleusercontent.com\u002FlFhNxWRNBVYdAdv-xFsAfKBdnYPLg1PyEr0mIgJIi7riksRe1oYJGmefdWHhkcPS79C7xQJXb1srw0TJL7TvUUwMe7QxjPQj-w",[84],{"id":17,"title":18},{"id":86,"title":87,"pubDate":88,"logoUrl":8,"thirdParty":10,"imageUrls":89,"orgId":14,"branches":91,"description":95},"fc7647f6-7f12-4e33-a125-0ce4833eee0a","Matisse Pharmaceuticals krijgt akkoord voor dosisverhoging M6229 in septische patiënten","2022-09-07T17:05:47.063+02:00",[90],"https:\u002F\u002Forder.perssupport.nl\u002Ffile\u002Fpressrelease\u002F30e76681-639e-4fbd-b386-b506ba4fee17\u002Ffc7647f6-7f12-4e33-a125-0ce4833eee0a\u002FPersberichtMatissePharmaceuticalskrijgtakkoordvoorverhogendosisinsepsispatienten.pdf",[92],{"id":93,"title":94},"38100","Algemeen nieuws","Matisse Pharmaceuticals staat op het punt een derde dosisniveau te starten in een Fase I\u002FIIa studie met zijn lead compound M6229 bij septische patiënten. Geleen"]